Savara Inc. (SVRA)

NASDAQ: SVRA · IEX Real-Time Price · USD
2.36
-0.01 (-0.42%)
At close: Feb 3, 2023, 4:00 PM
2.27
-0.09 (-3.81%)
After-hours: Feb 3, 2023, 7:30 PM EST
-0.42%
Market Cap 269.14M
Revenue (ttm) n/a
Net Income (ttm) -39.16M
Shares Out 114.04M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 371,095
Open 2.30
Previous Close 2.37
Day's Range 2.27 - 2.40
52-Week Range 1.02 - 2.82
Beta 0.75
Analysts Buy
Price Target 4.08 (+72.88%)
Earnings Date Mar 28, 2023

About SVRA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Robert Neville
Employees 22
Stock Exchange NASDAQ
Ticker Symbol SVRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for SVRA stock is "Buy." The 12-month stock price forecast is $4.08, which is an increase of 72.88% from the latest price.

Price Target
$4.08
(72.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Savara Announces New Employment Inducement Grant

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new...

2 weeks ago - Business Wire

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending S...

3 months ago - Business Wire

Savara to Participate in Three Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate a...

3 months ago - Business Wire

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new...

5 months ago - Business Wire

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2...

5 months ago - Business Wire

Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will...

5 months ago - Business Wire

Savara Announces Resignation of Chief Medical Officer

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has res...

5 months ago - Business Wire

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the UK's Medicines and Healthcare Prod...

5 months ago - Business Wire

Savara Reports Second Quarter 2022 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending Ju...

6 months ago - Business Wire

Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poste...

7 months ago - Business Wire

3 Top Breakout Stocks to Add to Your Portfolio Now

Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.

Other symbols: HHSLGL
7 months ago - Zacks Investment Research

Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an Innovation...

8 months ago - Business Wire

Savara to Present at Jefferies Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...

8 months ago - Business Wire

After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

9 months ago - Zacks Investment Research

Savara to Present at H.C. Wainwright Global Investment Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...

9 months ago - Business Wire

Savara Reports First Quarter 2022 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending Mar...

9 months ago - Business Wire

Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it entered into a term loan agreement ...

10 months ago - Business Wire

Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a busi...

11 months ago - Business Wire

Savara to Present at Oppenheimer's 32nd Annual Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Op...

11 months ago - Business Wire

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...

1 year ago - Business Wire

Savara to Participate in Two Upcoming Investor Healthcare Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...

1 year ago - Business Wire

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter endi...

1 year ago - Business Wire

Savara to Present at the Jefferies London Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th...

1 year ago - Business Wire

Savara to Present at the Inaugural Piper Sandler Lung Day

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate i...

1 year ago - Business Wire

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new e...

1 year ago - Business Wire